Inclusion Criteria:

- Histologically confirmed endometrial carcinoma (from primary tumor) including any of
the following cell types:

- Endometrioid adenocarcinoma

- Serous adenocarcinoma

- Undifferentiated carcinoma

- Clear cell adenocarcinoma

- Mixed epithelial carcinoma

- Adenocarcinoma not otherwise specified

- Mucinous adenocarcinoma

- Squamous cell carcinoma

- Transitional cell carcinoma

- Mesonephric carcinoma

- Recurrent or persistent disease that is refractory to curative therapy or established
treatments

- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
conventional techniques or ≥ 10 mm by spiral CT scan

- Must have ≥ 1 target lesion to assess response as defined by RECIST

- Tumors within a previously irradiated field are designated as "non-target"
lesions in the absence of documented disease progression or a biopsy to confirm
persistence for ≥ 90 days after completion of radiotherapy

- Must have received 1 prior chemotherapeutic regimen for management of endometrial
carcinoma

- May have received 1 additional cytotoxic regimen for management of this disease

- Not eligible for a higher priority Gynecologic Oncology Group (GOG) protocol,
including any active GOG Phase III protocol for patients with endometrial carcinoma

- No history or evidence of CNS disease, including primary brain tumor or any brain
metastases upon physical examination

- GOG performance status (PS) 0-2 (for patients who have received 1 prior regimen) OR
PS 0-1 (for patients who have received 2 prior regimens)

- ANC ≥ 1,500/mcL

- Platelet count ≥ 100,000/mcL

- Creatinine ≤ 1.5 times upper limit of normal (ULN)

- Bilirubin ≤ 1.5 times ULN

- SGOT ≤ 2.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

- Urine protein:creatinine ratio < 1.0 OR urine protein < 1,000 mg by 24-hour urine
collection

- INR ≤ 1.5 OR in-range INR between 2 and 3 if patient is on a stable dose of
therapeutic warfarin

- PTT ≤ 1.5 times ULN

- Fasting cholesterol < 350 mg/dL

- Fasting triglycerides < 400 mg/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Seizures allowed provided they are controlled with standard medical therapy

- No active infection requiring antibiotics, except uncomplicated urinary tract
infection

- No active bleeding or pathologic conditions that carry high risk of bleeding, (e.g.,
known bleeding disorder, coagulopathy, or tumor involving major vessels)

- No serious, non-healing wound, ulcer, or bone fracture, including abdominal fistula,
gastrointestinal perforation, or intra-abdominal abscess within the past 3 months

- No prior underlying lesions that caused the fistula or perforation that have not
been corrected

- No prior interstitial pneumonitis

- No clinically significant cardiovascular disease, including any of the following:

- Uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg
or diastolic BP > 90 mm Hg

- Myocardial infarction or unstable angina within the past 6 months

- New York Heart Association class II-IV congestive heart failure

- Serious cardiac arrhythmia requiring medication

- Peripheral vascular disease ≥ grade 2

- No cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage
within the past 6 months

- No uncontrolled diabetes

- Hemoglobin A1C < 10

- No other invasive malignancies within the past 5 years, except nonmelanoma skin
cancer and other specific malignancies (e.g., localized breast, head and neck, or
skin cancer that completed treatment > 3 years prior to study and remain
disease-free)

- No significant traumatic injury within the past 28 days

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human or humanized antibodies

- Concurrent prophylactic or therapeutic anticoagulation* (e.g., warfarin) allowed

- Recovered from recent surgery, radiotherapy, or chemotherapy

- No prior bevacizumab or other VEGF pathway-targeted therapy

- No prior temsirolimus, everolimus, deforolimus, sirolimus, or any other mTor/PI3K
pathway-targeted therapy

- No prior non-cytotoxic chemotherapy for management of this disease, except hormonal
therapy

- At least 1 week since prior hormonal therapy directed at the malignant tumor

- No prior therapy that contraindicates this protocol therapy

- No prior radiotherapy to any portion of the abdominal cavity or pelvis within the
past 5 years, except treatment of endometrial cancer

- Prior radiotherapy for localized cancer of the breast, head and neck, or skin is
allowed, provided it was completed > 3 years prior to study entry and patient
remains free of recurrent or metastatic disease

- No prior chemotherapy for any abdominal or pelvic tumor within the past 5 years,
except treatment of endometrial cancer

- Prior adjuvant chemotherapy for localized breast cancer allowed, provided it was
completed > 3 years prior to study entry and the patient remains free of
recurrent or metastatic disease

- Prior treatment with an anthracycline (i.e., doxorubicin and/or liposomal
doxorubicin) allowed provided ejection fraction < 50%

- More than 28 days since prior major surgery or open biopsy

- More than 7 days since minor surgical procedures, fine needle aspirates, or core
biopsies

- At least 3 weeks since prior therapy directed at the malignant tumor, including
immunologic agents

- No concurrent major surgery

- No concurrent prophylactic filgrastim (G-CSF) or thrombopoietic agents

- No concurrent amifostine or other protective reagents